

Acutus Medical, Inc. (AFIB)

Corporate Presentation

Disclaimer

This presentation will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, the scope, progress, results and costs of developing our products or any other future products, the potential market size and size of the potential patient populations for our products, the timing and likelihood of success of obtaining product approvals, plans and objectives of management for future operations, the scope of protection we are able to establish and maintain for intellectual property rights covering our products, and future results of anticipated products, are forwardlooking statements.

These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements. Factors that may cause results to differ from these forward-looking statements are discussed under the Forward-Looking Statements section in the company's most recent 10K and other periodic filings with the Securities and Exchange Commission (SEC).

Any forward-looking statements provided during this presentation, including projections for future performance, are based on management's expectations as of today. Acutus undertakes no obligation to update these statements, except as required by applicable law.

Leading the Charge in Electrophysiology



We are a **therapy management company** developing comprehensive and innovative technologies to treat complex cardiac arrythmias


Our vision is to become the partner-of-choice to electrophysiologists through our broad portfolio of diagnostic and therapy solutions

Our Markets are Large, Growing, and Underpenetrated

Key drivers: Growing incidence and diagnosis of cardiac arrhythmias

Rising utilization of Western lifestyle self-monitoring devices Well-established Progressive disease, reimbursement in function of aging developed markets

Market is projected to grow double-digits from 2018 to 2025¹



Despite nearly ~1 million procedures in 2020... the market is under 5% penetrated²

1. Electrophysiology Mapping and Ablation Devices, Market Insights, US. Decision Resources Group M360EP0062, June 2020

2. Total prevalence pool of ~53M with ~972K treated in 2020 and 1.04M in 2019

Significant Opportunity in Complex Ablations

Largely treated with contact mapping-based radiofrequency (RF) ablation and cryoablation


~600K



Multiple treatment modalities to address this population with relatively inconsistent outcomes

D

С




5

Individualized Ablation for Improved Outcomes




Pulmonary Vein Isolation (PVI) Leaves questions about further targets outside the veins



Conventional contact mapping leaves large areas <u>undiagnosed</u> and <u>untreated or overtreated</u>

AcQMap

Direct visualization of heart's activity reveals actionable diagnostic information



Unique and differentiated capability to directly visualize extra-pulmonary vein activity (triggers) and diagnostic information on areas of abnormal activity (substrate)

Unique Electrophysiology Platform

AcQMap is the only system on the market designed specifically for the complex patient population

Non-Contact 3D Imaging & Mapping Catheter

Multi-modal Guidance Console

Open Platform Compatible with most EP Catheters




Comprehensive end-to-end suite of mapping, diagnostics, and therapy portfolio

AcQMap Clinical Data Helping to Fuel Adoption



A fundamentally different mapping approach & therapy strategy improves success rates

12-Month Success Rates (Freedom from AF)



Conventional, non-patient-specific contact-mapping

66%EU-PORIA (PFA)50%STAR-AF 2 (PVI+ lines)46%STAR-AF 2 (PVI+ CFAE)29%STAR-AF 2 (PVI)

Diagnostic Tools Enhance Therapy

- Ablation strategies will continue to evolve with new energy modalities like Pulsed Field Ablation (PFA) as well as new catheter designs
- ✓ AF therapy outcomes, particular in persistent AF and re-do patients, require advanced diagnostics
- Mapping will remain critical to procedural success regardless of energy delivery platform

Acutus Growth Strategy



Grow Addressable Market

~\$3.0 Billion

Total addressable procedure opportunity by 2025



Executing on new product development to address market unmet needs and portfolio opportunities Expand User Base

100+

Current Users of AcQMap



Driving same-store utilization growth and targeted installed base growth Increase Procedure Penetration

~30-50%

Per Procedure Revenue Uplift Opportunity




Portfolio expansion will enable greater share of procedure economics

Multiple Drivers to Support AcQMap Adoption and Strong Revenue Outlook

Strong Global Procedure Volume Ramp




~7,000 patients treated with AcQMap-guided therapy



Driving Improved Operational Performance






• Operating expenses are Non-GAAP (excludes restructuring, stock-based compensation, amortization of intangibles, acquisition related costs, and other adjustments)

· Cash burn excludes cash used in debt repayment and expenses related to debt restructuring as well as cash from disposition of assets

Full Year 2023 Outlook



Revenue Guidance		
	Full Year 2023	
	\$20-22 Million	



References



- Electrophysiology Mapping and Ablation Devices, Market Insights, US. Decision Resources Group M360EP0062, June 2020
- Total prevalence pool of ~53M with ~972K treated in 2020 and 1.04M in 2019
- Willems et al; Targeting Nonpulmonary Vein Sources in Persistent Atrial Fibrillation Identified by Noncontact Charge Density Mapping: UNCOVER AF Trial: *Circ Arrhythm Electrophysiol.* 2019;12:e007233
- Mansour M, et. al; Persistent atrial fibrillation ablation with contact force sensing catheter: The prospective multicenter PRECEPT Trial, JACC: Clinical Electrophysiology (2020)
- De Lurgio D et. al; Hybrid Convergent Procedure: Epicardial and Endocardial Ablation for the Treatment of Persistent Atrial Fibrillation -CONVERGE Randomized Controlled Clinical Trial Results, HRS Late-Breaking Clinical Trials (2020)
- Europace. 2023 Jul 4;25(7):euad185. doi: 10.1093/europace/euad185. EUropean real-world outcomes with Pulsed field ablatiOn in patients with symptomatic atRIAI fibrillation: lessons from the multi-centre EU-PORIA registry
- Verma A, et al; Approaches to Catheter Ablation for Persistent Atrial Fibrillation N Engl J Med 2015;372:1812-22. Estimated from KM curve data available in NEJM
- Shi R. et al., Individualized ablation strategy to treat persistent atrial fibrillation: Core-to-boundary approach guided by charge-density mapping 2021 Jun; 18(6):862:870
- Betts et al. Treatment of pathophysiologic propagation outside of the pulmonary veins in retreatment of atrial fibrillation patients: Recover AF study. Europace. 2023. doi:10.1093/europace/euad097
- Chaumont C. et al., Heart Rhythm 2022, Vol 19, Issue 5 (suppl.)

Stay Connected With Acutus



Issuer Acutus Medical, Inc.

Exchange / Ticker NASDAQ: AFIB

Investor Contact

Caroline Corner 415-202-5678 caroline.corner@westwicke.com investors@acutus.com



linkedin.com/company/acutus-medical-inc-/



@AcutusMedical

@AcutusMedical



Acutus Medical



www.acutusmedical.com